Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines.

Mouawad F, Gros A, Rysman B, Bal-Mahieu C, Bertheau C, Horn S, Sarrazin T, Lartigau E, Chevalier D, Bailly C, Lansiaux A, Meignan S.

Oral Oncol. 2014 Feb;50(2):113-9. doi: 10.1016/j.oraloncology.2013.11.003. Epub 2013 Nov 26.

PMID:
24290982
[PubMed - in process]
2.

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S.

Invest New Drugs. 2014 Jul 11. [Epub ahead of print]

PMID:
25008900
[PubMed - as supplied by publisher]
3.

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C.

Cancer Res. 2008 Dec 1;68(23):9845-53. doi: 10.1158/0008-5472.CAN-08-2748.

PMID:
19047165
[PubMed - indexed for MEDLINE]
Free Article
4.

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

Kruczynski A, Pillon A, Créancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N.

Leukemia. 2013 Nov;27(11):2139-48. doi: 10.1038/leu.2013.108. Epub 2013 Apr 9.

PMID:
23568148
[PubMed - indexed for MEDLINE]
5.

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly C, Guilbaud N.

Biochem Pharmacol. 2011 Dec 15;82(12):1843-52. doi: 10.1016/j.bcp.2011.08.028. Epub 2011 Sep 8.

PMID:
21924246
[PubMed - indexed for MEDLINE]
6.

Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N.

Biochemistry. 2011 Apr 19;50(15):3240-9. doi: 10.1021/bi200094z. Epub 2011 Mar 28.

PMID:
21413765
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N.

Invest New Drugs. 2011 Feb;29(1):9-21. doi: 10.1007/s10637-009-9328-3. Epub 2009 Sep 24.

PMID:
19777159
[PubMed - indexed for MEDLINE]
8.

Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines.

Kotowski U, Heiduschka G, Brunner M, Erovic BM, Martinek H, Thurnher D.

Oncol Lett. 2012 Jun;3(6):1326-1330. Epub 2012 Mar 14.

PMID:
22783443
[PubMed]
Free PMC Article
9.

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.

Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y, Zheng D.

BMC Cancer. 2011 Feb 3;11:54. doi: 10.1186/1471-2407-11-54.

PMID:
21291526
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evidence-based radiation oncology in head and neck squamous cell carcinoma.

Corvò R.

Radiother Oncol. 2007 Oct;85(1):156-70. Epub 2007 May 4. Review.

PMID:
17482300
[PubMed - indexed for MEDLINE]
11.

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group.

Curr Oncol. 2010 Jun;17(3):37-48.

PMID:
20567625
[PubMed]
Free PMC Article
12.

The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.

Heiduschka G, Lill C, Schneider S, Seemann R, Kornek G, Schmid R, Kotowski U, Thurnher D.

Strahlenther Onkol. 2014 May;190(5):472-9. doi: 10.1007/s00066-014-0600-x. Epub 2014 Feb 21.

PMID:
24557056
[PubMed - indexed for MEDLINE]
13.

An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.

Chelouah S, Monod-Wissler C, Bailly C, Barret JM, Guilbaud N, Vispé S, Käs E.

PLoS One. 2011;6(8):e23597. doi: 10.1371/journal.pone.0023597. Epub 2011 Aug 10.

PMID:
21853156
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.

Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P, Bailly C, Marchetti P.

Apoptosis. 2012 Apr;17(4):364-76. doi: 10.1007/s10495-011-0681-2.

PMID:
22127645
[PubMed - indexed for MEDLINE]
15.

Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW.

Clin Cancer Res. 2006 Mar 15;12(6):1897-905.

PMID:
16551875
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.

Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, Nathan CO.

Mol Cancer Ther. 2009 Aug;8(8):2255-65. doi: 10.1158/1535-7163.MCT-08-1184. Epub 2009 Jul 22.

PMID:
19625495
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E.

Invest New Drugs. 2013 Apr;31(2):273-84. doi: 10.1007/s10637-012-9852-4. Epub 2012 Jul 19.

PMID:
22810221
[PubMed - indexed for MEDLINE]
18.

A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.

Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M, Vispé S, Bréand S, Guilbaud N, Barret JM, Bailly C.

Leuk Res. 2010 Oct;34(10):1383-9. doi: 10.1016/j.leukres.2009.12.021. Epub 2010 Jan 22.

PMID:
20096930
[PubMed - indexed for MEDLINE]
19.

Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.

Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I.

Oral Oncol. 2006 Aug;42(7):675-84. Epub 2006 May 30.

PMID:
16731029
[PubMed - indexed for MEDLINE]
20.

99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.

Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1832-41. doi: 10.1007/s00259-011-1857-2. Epub 2011 Jun 10.

PMID:
21660624
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk